Spelling suggestions: "subject:"highly Active"" "subject:"mighly Active""
11 |
Reasons for refusing antiretroviral therapy before completion of tuberculosis treatment at Pigg's Peak Hospital, Swaziland.Phiri, Elias January 2013 (has links)
Thesis (MPH)--University of Limpopo, 2013. / Statistics from Pigg’s Peak Hospital, in Swaziland, continue to show an improvement in the uptake of HIV testing among TB patients, as well as a very high rate of HIV co-infection among the TB patients. The unit’s reports also show a low uptake of antiretroviral therapy among the HIV co-infected TB patients, and high death rates. Most of these deaths occur among HIV co-infected TB patients who have not yet initiated ART despite being on TB treatment. Anecdotal evidence suggests that there is reluctance and refusal by a considerable proportion of TB/HIV co-infected patients to take TB treatment and ART concurrently, and that they prefer to commence ART after completing TB treatment. No study has ever been conducted in Swaziland to determine the reasons for refusal of ART initiation prior to the completion of TB treatment among HIV co-infected TB patients.
Aim
The aim of this study was to explore the reasons for refusing antiretroviral therapy among HIV co-infected tuberculosis patients, prior to the completion of tuberculosis treatment, at Pigg’s Peak Hospital, in Swaziland.
Methods
A qualitative descriptive study was conducted in order to generate information on the subjects’ experiences and views on the concurrent taking of tuberculosis and antiretroviral medicines. A sample of nineteen HIV co-infected TB patients was purposefully selected to answer the research question.
Results
The most common reasons given by the respondents for refusing ART initiation during TB therapy were their un-readiness for ART, especially because ART must be taken for life, the perception that one was still in good health, the fear of adverse outcomes being precipitated by combining ART with TB medicines, a preference of traditional medicines, and health systems-related problems. Other reasons were: a lack of food, substance abuse, a fear of the increased pill burden, a denial of the HIV-positive status, and problems related to treatment supporters.
Conclusion
In TB/HIV co-infection care settings, comprehensive Pre-ART counseling must be integrated with interventions that address the specific barriers to ART initiation faced by clients; to improve the acceptability of ART initiation during TB therapy to these HIV/TB co-infected patients.
|
12 |
Factors associated with intention to enrol into the HIV treatment programme in and around Lobatse, BotswanaTaylor, Tonye Benson 10 April 2014 (has links)
A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in partial fulfillment of the requirements for the degree Master of Family Medicine, October 2013 / Botswana has one of the highest HIV prevalence rates in the world, with 32% of
pregnant women and 24% of adults in the general population living with HIV. Although
antiretroviral therapy (ART) or HIV/AIDS treatment is widely available in the public sector in
Botswana, not all treatment-eligible patients utilise the services in a timely manner. The study
aims to identify the factors associated with the intention of already screened HIV positive/AIDS
patients, who met the government criteria, to enrol into the HIV treatment programme in
Lobatse, Botswana.
Methods: A Cross-sectional descriptive study was used, conducted at the Infectious Disease
Control Clinic, Athlone Hospital, Lobatse over a 6-month period. A questionnaire was
administered on systematically sampled participants, who met Botswana National antiretroviral
treatment or HIV/AIDS treatment guidelines.
Results: A total of 342 participants were enrolled, mostly female (67.3%) and single (50%).
Majority of the participants were age 35-44 years (17%), attained up to primary level education
(44%) and were mostly unemployed (54%). A majority (59%) intended to enroll into ART or
HIV/AIDS treatment programme due to sickness, while others were motivated by voluntary
testing and counseling (24%). The majority of the respondents received post-test counseling
(97.3%) and most was motivated to seek ART or HIV/AIDS treatment (88.3%). Only (60%)
disclosed their status to their relative. Although most participants (59.6%) were willing to be
linked to care and support, most (65.1%) were ignorant of support groups and services available
for them.
Discussion: Although there is increasing access to ART or HIV/AIDS treatment, most
participants still wait until they are sick or have symptoms before they enroll into ART.
Supportive post-test counseling and conducive family environment were some of the enabling
factors. Distance to health facilities and long queues are barriers to accessing care as well as
stigma and discrimination. The most significant reasons for not continuing with the treatment
were health facilities being far from place of residence and queuing for a long time to see a
doctor and or collect medications.
Conclusion: Sickness, public education, supportive family environment and effective post-test
counseling were found to be significant motivators for intention to enroll into ART. Perceived
barriers to accessing treatment include distance and time spent in the health facilities.
Interventions are required to reduce stigma, bring health facilities nearer to the people, and
increase efficiency in health facilities and increase access and utilization of the care and support
groups.
|
13 |
Occurence and determinants of treatment faiure in antiretroviral therapy at Tshwane District HospitalSokoya, Temitope 03 1900 (has links)
A research report submitted to the Faculty of Health Sciences, University of the
Witwatersrand, Johannesburg, in partial fulfilment of the requirements for the degree of
Master of Science in Pharmaceutical Affairs
Johannesburg, 2012 / Objective: To determine the proportion of HIV+ patients who fail treatment on a
yearly basis in a 5-year treatment cohort in Tshwane District Hospital and to
determine the correlation of treatment failure with variables routinely measured at the
clinic namely WHO stage, CD4 count, HIV viral load, age, gender, presence of
concomitant diseases, concomitant medication and distance travelled to clinic.
Design: A retrospective study with an analytical component was conducted using the
hospital records of adult patients receiving antiretroviral therapy in 2004 and followed
for 5 years (until 2009) at the Tshwane District Hospital.
Methods: All adult patients receiving antiretroviral therapy in 2004 were identified
and followed for the next 5 years till 2009 at Tshwane District Hospital. The
proportion of patients that failed treatment yearly was calculated. Univariate analysis
was used to compare all patients who failed at any time point with the patients who
did not fail at all for all variables. A repeated measures logistic regression model was
developed to determine the variables that impacted on the binary outcome, namely
treatment failure or not.
Results: Of the 1104 adult patients who were attending the TDH Immunology clinic
in 2004, 870 adults were receiving ARVs. 333 patients (38.28 %) experienced
treatment failure throughout the study period. 6.9 % (60/870) of the study population
failed virologically. 307 of the 870 patients (35.29 %) failed treatment
immunologically. 102 patients (11.72 %) experience treatment failure at the 12 month
time point, 37 patients(4.49 %) at the 24 month time point, 57 patients(6.93 %) at 36
month time point, 101 patients(12.27 %) at the 48 month time point and 140 patients
(7.01 %) failed treatment at 60 month time point. Univariate analysis showed
significant correlation between treatment failure and non-adherer, interrupting
treatment, defaulted treatment, viral load at baseline, 12, 24, 36, 48, 60 months, and
CD4 count at baseline, 12, 24, 36, 48, 60 months. In the multivariate analysis, there
was a significant association between short term stoppage of treatment (STSTOP)
(coefficient ratio = 1.41; p<0.001), long term stoppage of treatment (LTSTOP)
(coefficient ratio = 3.24; p<0.001), transfers from other health institutions (coefficient
ratio = 1.96; p<0.001), regimen (coefficient ratio = -0.1734) and treatment failure. The
change in log viral load at 12 months from baseline (LOGVLBL12) (coefficient ratio
=-1.7145; p<0.001) was highly significant for reaching the end point - treatment
v
failure. Older patients were less likely to fail treatment (coefficient ratio = -0.0517,
p<0.001) and patients with an advance stage of the disease (WHO stage 3 or 4)
were at a lower risk of failing treatment (coefficient ratio = -0.4175; P=0.008). The
CD4 count was significant in the univariate analysis P<0.01) and XTGEE (coefficient
ratio =- 0.0001; p<0.001). There was no significant correlation between gender, place
of residence, employment status and treatment failure.
Conclusion: More than one–third of the patients receiving treatment in TDH failed
treatment within the 5 year study period. The determinants of treatment failure are
age, WHO stage, transfer from other institutions, short term stoppage of treatment,
long term stoppage of treatment, CD4 cell count and the level of viral suppression
within the first year of treatment (LOGVLBL-12). This study reinforces the need for
identifying high risk patients earlier in treatment in order to implement strategies that
might strengthen adherence to treatment.
|
14 |
Breast hypertrophy and gynaecomastia in HIV-associated lipodystrophy, a problematic side-effect of life-saving antiretroviral therapyZinn, Richard Joseph January 2014 (has links)
A research report submitted to the Faculty of Medicine, University of the
Witwatersrand, in partial fulfillment of the requirements for the Degree of Master of
Medicine in the division of Plastic and Reconstructive Surgery.
Johannesburg 2014 / With 67% of the world’s human immunodeficiency virus (HIV) infected population
existing in Sub-Saharan Africa and recent access to highly active antiretroviral therapy
(HAART); demand for plastic surgical intervention in addressing HIV-associated
lipodystrophy has expanded dramatically. This study assessed the prevalence of
lipodystrophy in a random clinic cohort, the demand for surgical correction, and risk of
treatment non-compliance
A questionnaire and database cross-sectional review of 554 patients was performed over a
three-month period at the Themba Lethu Clinic, Johannesburg, South Africa.
A total of 479 patients completed the questionnaire, 83% were female. Nearly 90% of
patients were currently being treated, or had been treated with stavudine (d4T). The
prevalence of lipodystrophy was 11.7%. Nearly 5.9% of patients had considered stopping
treatment due to changes in body morphology following the onset of HAART, 47% of
patients interviewed would consider surgery to correct unwanted physical changes
following treatment with HAART. Male patients were satisfied by physical changes in
their body habitus following treatment (pre-treatment satisfaction 38% vs. post-treatment
satisfaction of 94%). Female patients had 6.5 times more breast hypertrophy related
symptoms than in their pretreatment state.
This study identified a prevalence of 11.7% of patients with HIV-associated
lipodystrophy. A total of 3.8% of all patients would consider non-compliance on the basis
of this side effect alone. The demand for surgical correction is significant, extends beyond
patients diagnosed with HIV-associated lipodystrophy, and needs to be addressed.
|
15 |
Incidence and risk factors for hepatotoxicity following antiretroviral initiation in patients attending Themba Lethu Clinic, JohannesburgMirira, Munamato 20 June 2012 (has links)
M.Sc. (Epidemiology), Faculty of Health Sciences, University of the Witwatersrand, 2011 / Background and Objectives
The advent of Highly Active Antiretroviral Therapy (HAART) has resulted in a significant reduction in HIV/AIDS related morbidity and mortality in sub-Saharan Africa. However, toxicities due to HAART continue to pose challenges to the success of different regimens. Severe hepatotoxicity is one of the significant adverse events occurring in patients on HAART. Information on the incidence and risk factors for severe hepatotoxicity in cohorts from resource poor settings is limited. It is against this background that we undertook the study to determine the incidence and explore factors associated with severe hepatotoxicity following HAART initiation in a South African cohort.
Materials and Methods
Secondary data analysis of a prospective cohort 9764 HIV-infected adult patients initiated on HAART at the Themba Lethu clinic antiretroviral rollout facility in Johannesburg, South Africa between 1st April 2004 and 30th June 2009 was conducted. Severe hepatotoxicity cases were identified within the first 12 months of initiating HAART as grade 3 or 4 elevation in baseline ALT levels. The incidence rate of severe hepatotoxicity was calculated and potential socio-demographic and clinical predictors were explored using Cox proportional hazard regression modelling.
Results
At baseline, 91.8% of patients were commenced on an efavirenz-based regimen while only 8.2% were on a nevirapine-based regimen. The median CD4 count at
v
initiation of HAART for this cohort was 80 cells/ mm3, a figure lower than the Department of Health (DoH) CD4 cut off for initiating HAART of 200 cells/ mm3.
The overall incidence rate of severe hepatotoxicity was 10.7 (95% CI: 8.7 – 13.1) cases per 1000 p-yrs of follow-up. The period with the highest risk of severe hepatotoxicity was within 2 months of initiating HAART. Incidence of severe hepatotoxicity was 21.1(95% CI: 12.7 – 34.9) cases per 1000 p-yrs among patients on a nevirapine-based regimen and 9.7 (95% CI: 7.8 – 12.1) cases per 1000 p-yrs in those on an efavirenz-based one.
The hazard for severe hepatotoxicity within the first year of initiating HAART was 2.17 times higher in individuals on a nevirapine-based regimen compared to those on an efavirenz-based regimen after adjusting for baseline ALT, baseline CD4, age and gender (HR = 2.17; 95%CI = 1.18 – 3.97; p = 0.013). Though imprecise, the estimate for baseline ALT category suggested an increased risk for severe hepatotoxicity in individuals with a baseline ALT more than 40 I.U/L compared to those with a baseline ALT of less than 40 I.U/L (HR = 1.63; 95%CI = 1.00 – 2.67; p = 0.050).
Conclusion
The results of the study suggest that severe hepatotoxicity following initiation of HAART in this cohort is low compared to other previously studied cohorts. The high incidence rate of severe hepatotoxicity in the first two months of initiating HAART necessitates the need for more frequent and careful monitoring of ALT levels early during therapy. Patients on a nevirapine-based regimen have a higher risk of developing severe hepatotoxicity when compared to their counterparts on an efavirenz-based regimen, a result consistent with findings from previous studies.
|
16 |
Profiling the risk factors of lactic acidosis in HIV positive adult patients on antiretroviral treatment in South Africa in the public sectorPadayachee, Neelaveni 20 June 2012 (has links)
M. Pharm., Faculty of Health Sciences, University of the Witwatersrand, 2011 / Background: According to the 2010 edition of the UNAIDS Report on the global AIDS epidemic, an estimated 320 000 (20%) fewer people died of AIDS-related causes in South Africa in 2009 than in 2004 due to the increase in availability of anti-retroviral medicines.(2) With this positive trend, the mindset should be shifted towards reducing adverse effects of ART. The need for permanent ART treatment and the significant increase in life expectancy have led to the observation of new, frequent, and sometimes severe drug-related adverse effects.(4) One of the most challenging and potentially dangerous side-effects is hyperlactataemia (Hlac) that may evolve to lactic acidosis (LA)(5) ART–associated Hlac may be asymptomatic, or symptomatic which in the extreme case can progress to life threatening acidosis. The latter, i.e. lactic acidosis is a fairly frequent and often misdiagnosed or under diagnosed and potentially fatal side effect of ARTs. (6)
Objectives: To explore the relationship between Hlac/LA and gender, weight, dosage CD4 and regimen alterations in HIV patients on ARTs and to compare the earlier regimens to the revised regimens as independent risk factors for Hlac and LA. Sample size would be based on the hypothesis that newer regimens would reduce the incidence of Hlac and LA.
Methods: A Retrospective study was conducted by reviewing 3 741 patient files from August 2004 to December 2007. This study was to assess the incidence and risk factors of Hlac/LA. Hlac was defined as a venous lactate measurement of ≥2.3mmol/L and LA was ≥5mmol/L. Immunological, virological, haemotological and biochemical results were recorded for all the patients. A second phase involved a Prospective study. Patients who were on treatment for >12 months were randomly selected from the queue at the clinic between the September 2008 and December 2009. Immunological, virological, haematological and biochemical information was recorded for all patients selected. Analysis involved descriptive statistics, comparison of means, frequency analysis and multivariate analysis.
Results: Two-hundred and thirty two patients were identified with elevated lactate levels in the retrospective study. The incidence was 6.2% in this population, with gastro-intestinal symptoms, peripheral neuropathy, abdominal tenderness, rash and upper respiratory tract infection being the significant symptoms. The major risk factor was a low CD4 count. The prospective study included 292 patients with 24.3% with Hlac/LA with peripheral neuropathy (p 0.209), gastrointestinal symptoms (nausea, vomiting) (p 0.148) and abdominal tenderness (p 0.214) were the most significant symptoms. In terms of the hypothesis that newer regimens would lower the incidence of elevated lactate levels by 50%, the observed incidence of 24.3% is no different from previously reported rates. This therefore shows that although regimen changes have been implemented the overall incidence of Hlac appears to be unchanged but the LA rate was found to be significantly lower than before, 6.8 cases per 1000 patient years vs ±19 cases per 1000 person years.(16) Gastro-intestinal symptoms but not peripheral
iv
neuropathy; with low CD4 count, weight loss and low weight on entry were the significant risk factors, which is most likely representative of advanced disease. Conclusions: Although newer regimens have been introduced, Hlac/LA still exist. Healthworkers need to be on high alert for Hlac/LA particularly if a patient enters into the ART program with a low CD4 count and a low weight
|
17 |
A study on the barriers to Anti-retroviral Therapy adherence among Human Immunodeficiency Virus infected adolescents in Gaborone (Botswana)Ndiaye, Maimouna January 2012 (has links)
A research report submitted to the Faculty of Health Sciences, University of the
Witwatersrand, Johannesburg, in partial fulfillment of the requirements for the degree of
Masters of Public Health in the field of Health Measurement
22nd February, 2012 / Introduction: Barriers associated with good adherence to Antiretroviral Therapy (ART) among
human immunodeficiency virus (HIV) infected adolescents are multiple and complex. Those
barriers contribute to low adherence levels putting infected adolescents at risk of developing
resistance and decreasing their survival time. Patients care givers psychosocial and demographic
variables, medication related factors and health care delivering factors are among the barriers
that correlate with non adherence to antiretroviral drugs (ART’s) among HIV infected
adolescents. Those barriers vary across individuals within the same population of adolescents.
This study was conducted to determine the level of adherence among HIV infected adolescents
on ART and to identify barriers associated with non adherence among this population attending
the Botswana Baylor Children’s Clinical Center of Excellence (COE) in Gaborone, Botswana.
Materials and methods: A cross sectional analytical study using quantitative data was
performed. A structured, self administrated questionnaire adapted from the AIDS Clinical Trials
Group (ACTG) was used to identify the barriers while the socio-demographic and clinical data
were retrieved from study participants’ medical records. The adherence level was estimated
using the pharmacy pill count technique. The adolescents aged 13 to 18 years receiving ART for
more than 6 months and attending the ART National Program at the time of the study and who
did assent and had their care givers consent to participate in the study were included in the
analysis.
Results: A high adherence level (75.6%) was reported among the study participants. Besides
gender, no other socio-demographic and clinical variables showed association with non
adherence. Male adolescents were found to be 70% less likely to adhere to their medication than
their counterpart females [p= 0.020, OR=0.30, 95% CI (0.10 – 0.85)]. Furthermore adolescents
v
who missed a dose because their pills were not collected from the pharmacy either by themselves
or by their care givers were 77 % less likely to adhere to their ART medication than those who
did not miss a dose because they had their medication collected [p= 0.019, OR= 0.23, 95%CI
(0.064 – 0.837)].
Conclusion: A high proportion of HIV infected adolescents attending the Baylor Center of
Excellence ART National Program were adherent to their medication. Despite the high level
adherence to ART among this age group, interventions to improve adherence level should be
designed with a focus on male adolescents and to reinforce counseling of care givers and
adolescents about the hazards of poor adherence to treatment. Further research is however,
needed to elucidate more about the two main barriers that were found to be significantly
associated with non adherence among adolescents at Botswana Baylor Children’s Clinical Center
of Excellence: male-gender and medication collection from the pharmacy.
|
18 |
Investigation of the method of "mixed" pill counts as a tool to detect deliberate masking of non-adherence to antiretroviral therapy at Ntshembo Clinic, Mamelodi HospitalAdeyinka, Titilope Adetola January 2011 (has links)
Thesis(MSc(Med)(Pharmacy))--University of Limpopo (Medunsa Campus), 2011. / High levels of adherence to ART are essential for maximal suppression of viral replication
and avoidance of drug resistance. Pill counts are an indirect, objective method of assessing
adherence. Patients can invalidate pill counts by manipulating the number of tablets
returned. This paper describes a pilot study which investigated the ability of ‘mixed’ pill
counts to detect deliberate masking of non-adherence to ART at a public sector ARV Clinic
in Pretoria, South Africa. Seventy-eight adult patients on a first line regimen of ART were
recruited. At the first return visit, a standard pill count was performed and adherence (% of
tablets taken) was calculated. For the repeat prescription, three days’ extra supply was
dispensed without the patients’ knowledge. At the second return visit, a ‘mixed’ pill count
was performed and adherence was calculated. Patients were grouped into three categories
based on calculated adherence: truthfully non-adherent (<100% adherence), adherent
(100% adherence) and ‘over-compliant’ (>100% adherence, i.e. returning to the clinic with
fewer tablets than required). Exploratory interviews were conducted with truthfully nonadherent
and over-compliant patients to obtain explanations for discrepancies in pill counts.
Twenty-nine (37%) patients completed the study. Reasons for drop-out or discontinuation
from the study included the issue of prescriptions for 2-3 months’ ARV supply, missed
appointments, regimen changes and failure to return remaining tablets to the clinic. Eleven
patients (38%) were identified as over-compliant in one or more of the ARVs in their
regimen. Nine of these patients agreed to be interviewed, of which three admitted to
manipulating their tablet numbers. Reasons for manipulation included: being ’fine now’ and
not in need of ARVs; changes in body shape; possibility of the social grant being terminated
if non-adherent; getting a new supply and no need for remaining ARVs; knowing that the
tablets would be counted for the study. This pilot study indicated that the ‘mixed’ pill count
method is capable of detecting deliberate masking of non-adherence. Applying this method
to a larger sample may better estimate the frequency of pill count manipulation by patients
and help gain insight to reasons for this behaviour and the extent of actual non-adherence.
Key words: dumping, manipulation, masking, over-compliance, HAART
|
19 |
Outcomes of late initiation of antiretroviral therapy in Ugandan-HIV -infected children treated at Mildmay Jajja homeNabukenya, Jennifer Maryann SSengooba January 2011 (has links)
Thesis (MPH)University of Limpopo (Medunsa Campus), 2011. / INTRODUCTION: Antiretroviral therapy (ART) has been proven to significantly improve the quality and quantity of lives of patients infected with HIV. However, several barriers exist that prevent children from being initiated on treatment on time. Studies in adults have shown that the timing of treatment influence outcomes of ART; but little is known about this in children. Hence, the need for this study.
The purpose of this study was to characterize the outcomes of late initiation of ART in HIV- positive children seen at the Mildmay Jajja Home center.
METHODOLOGY: The study was a cross-sectional survey involving all children who were initiated at the Mildmay Jajja Home in 2005 and had had been on ART for at least 18 months. Two sets of data were collected, for the children on ART: their age and sex were recorded. In addition, based on the Ugandan clinical guidelines for ART, children were grouped into two groups; those 6 six years and below; and those above 6 years. Clinical variables recorded were baseline and repeated measurements of bodyweights, and CD4 counts; weight and CD4 counts at the time of initiation of ART, at 12 months and at 18 months. For the care providers: their age, gender, education level, relationship to the child was recorded. Three outcomes of treatment were assessed, adherence level by the 12th month on treatment; hospitalisation by the 12th month (during the first 12 months of treatment); and survival or death at by the 12th and 18th month on treatment.
RESULTS: In total, 114 children were included in the sample. Among them, 54.4% of children were initiated late. Based on age, children 6 years old and younger were more likely and significantly initiated late as compared to those over 6 years old as about 70% of them were actually initiated late. Based on sex, female children older than 6 years were significantly initiated late as compared to boys. The characteristics of care providers that were associated with children being initiated late were being male, less than 40 years old, with a primary school level of education, and not knowing their own HIV status.
With regard to outcomes of the treatment, adherence, hospitalisation, and survival were assessed. Overall, 59.4% of children achieved an adherence level of 90% or more; 17.3% of children had been hospitalised at least once; and the mortality was 17.5% during the 2 year period covered by the study. Adherence was influenced slightly by the timing of the start of the treatment since less than half (46.34%) of those initiated late achieved an adherence level of 90% or more as compared to over 53% among those initiated timely. Though there was not statistically significant difference, adherence was slightly better in children whose care providers were biological parents, whose HIV status was known as positive, and female. With regard to hospitalisation, children less than 6 years were significantly more hospitalised than the older ones; their care providers were relatives, not educated, and of unknown HIV status. Those initiated late were significantly more hospitalised than those initiated timely (63.15% versus 36.84%, p=0.03).
With regard to survival, the majority of children who died were over 6 years old, and female. The majority of their care providers were female, under 40 years old, and known HIV-positive. In children initiated late, the mortality was 50% (n=14) and 83.3% (n=6) respectively by the 12th and 18th month of treatment as compared to those initiated timely.
In conclusion, 54.4% of children were initiated late. Late initiation was associated with negative outcomes such as low adherence to treatment as less than half of them achieved a adherence level of 90% or more; hospitalisation as those initiated late were significantly more hospitalised than those initiated timely; and high mortality since among those who died, 50% and 83.3% of deaths occurred respectively by the 12th and 18th month of treatment among those initiated late. In order to minimize the probability that the majority of children are initiated late, a general awareness campaign should be directed at the general public so that they can be sensitized to the need to bring children to medical attention as soon as possible
|
20 |
The prevalence of established factors associated with adherence to Highly Active Antiretroviral Therapy (HAART) in non-adhering patients at the ARV clinic of Madzikane KaZulu Memorial HospitalAnizoba, O. O. 22 July 2015 (has links)
Background
Adherence to HAART is key to any successful HAART programme. In Madzikane KaZulu Memorial Hospital ARV Clinic, there is an increasing number of patients on HAART and an increasing number of patients still awaiting HAART initiation. With the paucity of healthcare personnel in this rural district hospital, suboptimal patient’s preparation for HAART often occurs, and the HAART defaulter rate is on the increase. This is may be attributed to an interplay of factors affecting HAART adherence.
Aim and Objectives
The aim of this research was to determine the prevalence of established factors associated with adherence to Highly Active Antiretroviral Therapy (HAART) in non-adhering patients at the Madzikane KaZulu Memorial Hospital (MKMH) ARV clinic.
The objectives were:
• To conduct an audit on all case files of patients on HAART over the study period.
• To explore the behavioural aspects of poor HAART adherence in a focused group discussion.
• To describe the factors associated with good HAART adherence
Methods
Study design: A cross-sectional descriptive study which focused on determining the prevalence of established factors( patient-related, therapy-related and facility-related factors) affecting HAART adherence at the ARV clinic was carried out among identified HAART non-adhering patients. Patients that were not adhering with HAART between the period of January 2009 and December 2010 were selected for the study. These patients were 19 years or more and had been on HAART for at least two months. The study was carried out between November and December 2010. The result of the focused group discussion was utilized to refine the development of the questionnaire.
Setting: The study was conducted at the Madzikane KaZulu Memorial Hospital ARV clinic. This is a modern 269 bed district hospital in the Mount Frere, Alfred Nzo district, Eastern Cape Province of South Africa. This is a predominantly rural region.
Results:
Data for analysis was provided by 215 patients that fulfilled the inclusion criteria. The prevalence rate of the factors affecting HAART adherence at the hospitals ARV clinic was 24%. A total of 60% of the patients were females. Majority of the patients (86.1%) had treatment supporters, and more than half of the patients (57.2%) were unemployed and not on disability grant. A total of 62.8% of the patients prefer to take their ARV at a clinic near them, and the majority of these patients (96.3%) want to start taking their ARV in a nearby clinic within 6months. The female gender, unemployment not on disability grant, longer period on HAART, Regimen 1A ARV( stavudine or tenofovir plus lamivudine and efavirenz according to the National ART guideline 2004 and its modified version of April 2010) single marital status and probably poorly selected unprepared treatment supporters, are associated with poor HAART adherence at this ARV clinic.
Conclusion
The study revealed that the prevalence rate of the factors affecting HAART adherence at the Madzikane KaZulu Hospital ARV clinic was 24% amongst HAART non-adhering patients. These patients had the prevalence rate of patient-related factors (12.4%) more than double of the prevalence rates of therapy related factors (5.8%), and facility related factors (5.7%). Topmost amongst the associated factors for not adhering to HAART were: not belonging to a support group, the pills making the patient feel unwell, and the ARV clinic being too far from where the patients live. Efforts should be targeted at enrolling the patients in support groups, encouraging the use of HAART regimens that have good tolerability profiles, and establishing the down referral.
|
Page generated in 0.0439 seconds